Who Paid My Doc Search
Menu
Organisation paid for research Program year 2022 Source: CMS Open Payments

Summit Research Network Management Inc

Neither a doctor nor a teaching hospital

Research payments

$774,558

35 payments

Through program year 2022, Summit Research Network Management Inc is reported as receiving $774,558 in research payments, across 35 payments.

By program year

4 rows
Year Kind Amount Payments
2022 Research $117,995 1
2021 Research $59,867 9
2020 Research $305,708 12
2019 Research $290,988 13

Breakdown

Who paid Research payments · program years 2019–2022
  1. Otsuka Pharmaceutical Development & Commercialization, Inc. $462,349 2 payments
  2. ACADIA Pharmaceuticals Inc $130,573 22 payments
  3. Merck Sharp & Dohme Corporation $117,995 1 payment
  4. Biohaven Pharmaceuticals, Inc. $63,641 10 payments
Studies the money was for Research payments · program years 2019–2022
  1. A Phase 3, Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Trial Evaluating the Efficacy, Safety, and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder (Trial 405-201-00014) $247,169 1 payment
  2. A Phase 3, Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Trial Evaluating the Efficacy, Safety, and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficithyperactivity Disorder Trial 405-201-00014 $215,180 1 payment
  3. A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine na Adults $117,995 1 payment
  4. Acp-103-059 $108,084 20 payments
  5. A Phase 2/3 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention $59,867 9 payments
  6. Acp-103-042 $14,989 1 payment
  7. Acp-103-059 $7,500 1 payment
  8. A Phase 2/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention $3,774 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2022

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record